220 related articles for article (PubMed ID: 37962962)
41. Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies.
Longato E; Bonora BM; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Diabetes Res Clin Pract; 2021 Sep; 179():109024. PubMed ID: 34454002
[TBL] [Abstract][Full Text] [Related]
42. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
43. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
[TBL] [Abstract][Full Text] [Related]
44. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
46. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
47. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A; Lanzinger S; Chia-Hui Tan E; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Ha KH; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; Nyström T; Niskanen L; Linnemann Jensen M; Hoti F; Klement R; Déruaz-Luyet A; Kyaw MH; Koeneman L; Vistisen D; Carstensen B; Halvorsen S; Langslet G; Fazeli Farsani S; Patorno E; Núñez J;
Diabetes Metab; 2023 Mar; 49(2):101418. PubMed ID: 36608816
[TBL] [Abstract][Full Text] [Related]
48. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
49. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
[TBL] [Abstract][Full Text] [Related]
50. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
51. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
Zerovnik S; Kos M; Locatelli I
Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
[TBL] [Abstract][Full Text] [Related]
52. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Melzer Cohen C; Schechter M; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Fishkin A; Rosenzweig D; Chodick G; Karasik A; Mosenzon O
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1153-1162. PubMed ID: 37382938
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
54. Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.
Kohsaka S; Takeda M; Bodegård J; Thuresson M; Kosiborod M; Yajima T; Wittbrodt E; Fenici P
J Diabetes Investig; 2021 Jan; 12(1):67-73. PubMed ID: 32530554
[TBL] [Abstract][Full Text] [Related]
55. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
Kim J; Han K; Kim B; Baek KH; Song KH; Kim MK; Kwon HS
Diabetes Res Clin Pract; 2022 Dec; 194():110187. PubMed ID: 36442545
[TBL] [Abstract][Full Text] [Related]
56. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
57. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
[TBL] [Abstract][Full Text] [Related]
58. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
[TBL] [Abstract][Full Text] [Related]
59. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
Ng PY; Ng AK; Ip A; Wu MZ; Guo R; Yiu KH
Crit Care Med; 2023 Aug; 51(8):1074-1085. PubMed ID: 37026864
[TBL] [Abstract][Full Text] [Related]
60. Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study.
Huang ST; Bair PJ; Chang SS; Kao YN; Chen SN; Wang IK; Chiu CW; Chang CT; Shih YH; Li CY; Yu TM
Clin Pharmacol Ther; 2024 Jan; 115(1):95-103. PubMed ID: 37804230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
